Coherus Biosciences | CHRS - Créances Commerciales





Créances Commerciales Changement Date
AbbVie USD 12.48B 110M 2026-03
Acadia Pharmaceuticals USD 166.33M 17.95M 2026-06
Akebia Therapeutics USD 47.03M 19.19M 2025-12
ALKERMES USD 456.48M 48.85M 2026-06
Alnylam Pharmaceuticals USD 912.74M 28.78M 2026-06
Amarin USD 126.83M 477K 2025-12
Amgen USD 10.23B 1.09B 2026-06
Baxter International USD 1.86B 158M 2026-06
Biogen USD 1.79B 76.6M 2026-03
BioMarin Pharmaceutical USD 1.06B 157.13M 2026-06
Bristol-Myers Squibb USD 13.83B 535M 2026-06
Coherus Biosciences USD 18.42M 232.08M 2025-12
Eli Lilly USD 23.48B 2.3B 2026-06
Fujifilm JPY 887.02B 64.37B 2026-03
Gilead Sciences USD 5.06B 314M 2026-06
Ironwood Pharmaceuticals USD 81.89M 5.68M 2024-12
Merck USD 12.21B 435M 2026-03
Myriad Genetics USD 115.3M 2.7M 2025-12
Pacira USD 132.42M 6.78M 2026-06
Perrigo USD 697.1M 84.3M 2026-03
Pfizer USD 16.19B 19M 2026-06
PTC Therapeutics USD 219.92M 38.3M 2026-03
Regeneron Pharmaceuticals USD 6.57B 834.4M 2026-06
Sarepta Therapeutics USD 393.8M 154.11M 2026-06
Teva Pharmaceutical Industries USD 3.49B 100M 2026-06
Vertex Pharmaceuticals USD 2.13B 138.2M 2026-06
Xencor USD 42.23M 30.23M 2026-06
Zoetis USD 1.57B 65M 2026-06